The 2 most intensely investigated co-inhibitory checkpoints in this new era of cancer immunotherapy are cytotoxic T lymphocyte–associated protein 4 (CTLA-4)/B7 and PD-1/PD-L1. Here, PDCD1 is linked to cancer.